Emcure Pharmaceuticals Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/f8208vhjxyyxs6k21lkavn3v.pdf

Key Takeaways


Domestic Business: Sanofi Fill, Field Force Build

Satish Mehta: "Overall, our aspiration is to be a top 10 player in India not just in terms of revenues but also profitability."

International Markets: Canada Leads, ARV Bottoms

Satish Mehta: "During COVID time, Gagan, what happened, there was massive stockpiling which had taken place in all the countries which purchased ARV products. So, once those stocks had been liquidated, now the situation is getting back to normal."

Margins: New-Plant Drag, Operating Leverage Promise

Vikas Thapar: "As we guided, we did just about 20% EBITDA margins in Q1. You know, overall we anticipate our EBITDA margin profile to be there about in the range between 20% to 21%, factoring in some of these positive upsides that are there towards year-end."

Litigation & Balance-Sheet Clean-Up

Satish Mehta: "U.S. business is with tremendous amount of volatility, low predictability, highly capital intensive with low free cash flows. We have consciously taken a view to keep it out of Emcure and focus on the business of India, Emerging market along with Canada and EU(Europe), which are lot more stable and predictable."

Pipeline & Strategic Bets

Piyush Nahar: "Especially for Tenectase, we hold the global patent for use in stroke."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthFull-year overall revenue growth 20%+FY25
EBITDA margin20% to 21% range, factoring in positive upsidesFY25 year-end
Domestic growthGrow ~200 bps ahead of industryFY25
MR productivityPPM to reach closer to 7 (from 6.3 in Q1)FY25 year-end
New-plant breakevenKadu facility (global oral solids) reaches breakevenQ3 FY25
Interest costFull benefit of IPO cash deployment flows throughQ3 and Q4 FY25
Amphotericin B EU approvalApproval expectedCY2024
Semaglutide India filingGeneric filing targeted for day-1 launchMarch 2026

Key Metrics

MetricQ1 FY25
Revenue from operations₹1,815 cr, +17% YoY from ₹1,556 cr
Domestic revenue₹909 cr, +14% YoY; ex-FCM and ex-Sanofi grew 7% YoY and 8.4% QoQ
International revenue₹906 cr, +19.5% YoY, representing 50% of total revenue
Canada revenue₹294 cr, aided by Mantra acquisition; ex-Mantra base business grew double digits
Europe revenue₹358 cr, high single-digit growth
Gross margin62.4%, vs 63.6% in Q1 FY24; decline due to Sanofi business mix
EBITDA₹360 cr, +16% YoY
EBITDA margin19.8%, similar to Q1 FY24; full-year guidance 20% to 21%
PAT₹153 cr, +8.2% YoY; growth lower due to Mantra amortization and new facility depreciation
R&D spend~4% of revenue for the quarter; annual range 4% to 5%
Depreciation and amortization₹94 cr, up from ₹67 cr YoY due to Mantra acquisition and 4 new plants
Interest cost₹59 cr, expected to decline going forward on debt reduction
Net debt~₹850 cr post-IPO, vs ~₹1,550 cr prior to IPO
Gross debt~₹950 cr post-IPO, vs ~₹2,000 cr prior to IPO
Field force strength5,000 including managers, ~4,100 excluding managers; 1,200 added in last 18 months
MR productivity (PPM)6.3, vs 5.8 in Q1 FY24; expected closer to 7 by year-end
MR attrition rate20% to 30%, in line with industry
Total prescriber base growth~4.5% over the last 12 months
Differentiated products share (domestic)~53% of domestic revenue in FY24; Q1 similar
Differentiated products share (international)~one-third of international business in FY24; Q1 similar
New facilities margin drag~75 bps cumulative drag from four new facilities; expected to ease as utilization ramps
Kadu plant utilization~60%, expected to reach breakeven from Q3
Mehsana solids utilization~40%
Full-year revenue growth guidance20% plus
India organic growth target200 bps ahead of industry for full year
Tax rate26% expected for Q1
Outstanding tax dispute~₹250 cr, under appeal, no provisions taken